Skip to main content

Advertisement

Fig. 4 | Genome Medicine

Fig. 4

From: From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards

Fig. 4

Heatmap representation of the distribution of identified actionable variants in TCGA cohort. Somatic alterations of each sample (3184 samples) were analyzed as depicted in Fig. 1 and the resulting biomarker–drug associations were assigned to one of the six levels of evidence. Evidence in wild-type variants and resistances are not included in this representation (unless if the evidence is in level A1, e.g., NRAS, KRAS wild type in colorectal cancer). a The percentage of patients with at least one actionable variant at each level of evidence. b The cumulative percentage of patients with at least one actionable variant at increasing levels of evidence (from A1 to B3, x-axis). c Average (± standard deviation (SD)) number of actionable genes per patient at each level of evidence. d Combination of the data shown in ac panels depicted for the whole cohort, no distinction among cancer types

Back to article page